About cabozantinib
Tyrosine kinase inhibitor
Used for
- Treats advanced kidney cancer, alone or with nivolumab.
- Treats liver cancer after sorafenib.
- Treats differentiated thyroid cancer that has progressed after prior therapy.
Usual adult dose
60 mg by mouth once daily for kidney or liver cancer; 40 mg once daily with nivolumab. For thyroid cancer, 60 mg once daily.
Common side effects
- Diarrhea, nausea, vomiting, or constipation
- Tiredness, reduced appetite, or weight loss
- High blood pressure
- Hand-foot skin reaction or mouth sores
Important warnings
- Can cause serious bleeding, blood clots, or bowel perforation.
- May impair wound healing; treatment is paused before and after surgery.
- Can cause severe high blood pressure, liver problems, or jawbone damage.
- Avoid grapefruit and strong CYP3A4-modifying medicines; swallow tablets whole.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for four months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for four months after the last dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, may raise cabozantinib levels.
- Strong CYP3A4 inducers, such as rifampin, may lower cabozantinib levels.
- Grapefruit or grapefruit juice may increase cabozantinib levels.
- Warfarin and other anticoagulants may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.